AGENUS INC
AGENNasdaq
$5.01
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↓ -21.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$191.8M
Enterprise Value
$187.0M
P/E
2.4
P/S
1.5
P/B
—
EV/EBITDA
12.0
PEG
—
FCF Yield
-45.6%
Dividend Yield
—
Revenue (TTM)
$123.9M
Net Income (TTM)
—
Free Cash Flow (TTM)
-$87.5M
Gross Margin
—
Operating Margin
6.6%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
-0.1
Net Cash
$4.8M
Return 1Y
-25.4%
Company profile
Agenus Inc. discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer.
- CEO
- Garo H. Armen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 440
- Headquarters
- Massachusetts
- Website
- agenusbio.com
Management & directors
- Armen Garo HSee Remarks
- Klaskin Christine MPFO & PAO
- O'Day Steven JChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
AGEN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$33.7M↑ +40.2%
Diluted EPS$1.02↓ -199.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $88.2M | $295.7M | $98.0M | $156.3M | $103.5M | $114.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$117.2M | $25.7M | -$179.4M | -$159.5M | -$120.5M | -$20.2M |
| Net income | — | — | — | -$257.4M | -$232.3M | -$3.1M |
| Diluted EPS | -$1.05 | -$0.11 | -$15.64 | -$13.75 | -$10.59 | $0.00 |
| Operating cash flow | -$139.1M | $10.1M | -$175.4M | -$224.2M | -$158.3M | -$77.2M |
| Free cash flow | -$142.6M | -$23.7M | -$228.4M | -$234.2M | -$158.9M | -$77.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -133.0% | 8.7% | -183.0% | -102.1% | -116.4% | -17.7% |
| Net margin | — | — | — | -164.7% | -224.5% | -2.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.5M | $25.1M | $26.8M | $24.1M | $25.7M | $30.2M | $34.2M | $33.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.2M | -$31.5M | -$25.9M | -$13.3M | -$16.7M | -$4.5M | $14.4M | $15.1M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$2.52 | -$3.08 | -$1.95 | -$1.03 | -$1.00 | $1.94 | $0.09 | $1.02 |
| Operating cash flow | -$38.2M | -$53.3M | -$28.7M | -$25.6M | -$20.2M | -$14.7M | -$16.6M | -$36.0M |
| Free cash flow | -$38.6M | -$53.3M | -$28.7M | -$25.6M | -$20.2M | -$14.7M | -$16.6M | -$36.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -128.4% | -125.5% | -96.5% | -55.3% | -65.0% | -15.0% | 42.1% | 44.6% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
Jul 14, 2026
- 6d agoAGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivotfinance.yahoo.com
- 6d agoAgenus stock doubles as biotech narrows Phase 3 betthestreet.com
- 6d agoAgenus (AGEN) Moves 82.7% Higher: Will This Strength Last?finance.yahoo.com
- 6d agoAgenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?finance.yahoo.com
Jul 13, 2026
- 7d agoAGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatmentstocktwits.com
- 7d agoAgenus shares surge as company secures up to $340M to advance colon cancer trialproactiveinvestors.com
- 7d agoAgenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financingmarketbeat.com
- 7d agoAgenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)investorshub.advfn.com
- 7d agoWall Street closes lower as chip selloff and oil surge weigh on marketsproactiveinvestors.com
- 7d agoAgenus surges on study pivot; Apnimed lines up an IPObiopharmadive.com
- 7d agoAgenus rises premarket; Micron, Western Digital slidefinance.yahoo.com
- 7d agoAgenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancerfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | ARMEN GARO H· See Remarks | Award | 4,852 | $3.35 | $16,254.20 | filing |
| 2026-07-01 | HARRISON THOMAS L | Award | 8,547 | $3.58 | $30,623.90 | filing |
| 2026-06-26 | ARMEN GARO H· See Remarks | Award | 5,364 | $3.03 | $16,252.92 | filing |
| 2026-06-12 | ARMEN GARO H· See Remarks | Award | 4,925 | $3.30 | $16,252.50 | filing |
| 2026-05-29 | ARMEN GARO H· See Remarks | Award | 4,644 | $3.50 | $16,254.00 | filing |
| 2026-05-15 | ARMEN GARO H· See Remarks | Award | 4,540 | $3.58 | $16,253.20 | filing |
| 2026-05-01 | ARMEN GARO H· See Remarks | Award | 4,233 | $3.84 | $16,254.72 | filing |
| 2026-04-17 | ARMEN GARO H· See Remarks | Award | 3,403 | $4.79 | $16,300.37 | filing |
| 2026-04-03 | ARMEN GARO H· See Remarks | Award | 4,629 | $3.33 | $15,414.57 | filing |
| 2026-04-01 | HARRISON THOMAS L | Award | 9,228 | $3.32 | $30,627.73 | filing |
| 2026-03-20 | ARMEN GARO H· See Remarks | Award | 3,983 | $3.71 | $14,776.93 | filing |
| 2026-03-06 | ARMEN GARO H· See Remarks | Award | 4,994 | $2.96 | $14,782.24 | filing |
| 2026-02-20 | ARMEN GARO H· See Remarks | Award | 4,829 | $3.06 | $14,776.74 | filing |
| 2026-02-06 | ARMEN GARO H· See Remarks | Award | 5,027 | $2.94 | $14,779.38 | filing |
| 2026-01-23 | ARMEN GARO H· See Remarks | Award | 4,562 | $3.24 | $14,780.88 | filing |
| 2026-01-09 | ARMEN GARO H· See Remarks | Award | 3,780 | $3.91 | $14,779.80 | filing |
| 2026-01-02 | HARRISON THOMAS L | Award | 7,691 | $3.98 | $30,625.56 | filing |
| 2025-12-26 | ARMEN GARO H· See Remarks | Award | 4,942 | $3.31 | $16,358.02 | filing |
| 2025-12-12 | ARMEN GARO H· See Remarks | Award | 4,316 | $3.79 | $16,357.64 | filing |
| 2025-11-28 | ARMEN GARO H· See Remarks | Award | 3,587 | $4.56 | $16,356.72 | filing |
| 2025-11-14 | ARMEN GARO H· See Remarks | Award | 3,769 | $4.34 | $16,357.46 | filing |
| 2025-10-31 | ARMEN GARO H· See Remarks | Award | 4,120 | $3.97 | $16,356.40 | filing |
| 2025-10-17 | ARMEN GARO H· See Remarks | Award | 4,216 | $3.88 | $16,358.08 | filing |
| 2025-10-03 | ARMEN GARO H· See Remarks | Award | 3,951 | $4.14 | $16,357.14 | filing |
| 2025-10-01 | HARRISON THOMAS L | Award | 5,780 | $5.01 | $28,957.80 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.